Evidence map›Paper›PMID 35488723›Full record

ArticleESC heart failure2022

Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.

Yishay Wasserstrum, José M Larrañaga-Moreira, Cristina Martinez-Veira, Edward Itelman, Dor Lotan, Avi Sabbag, Rafael Kuperstein, Yael Peled, Dov Freimark, Roberto Barriales-Villa and 1 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Heart Failure in Hypertrophic Cardiomyopathy.Cardiac failure review · 2026
    Review
  5. Biomedicines · 2025
    Article
  6. Review
  7. Review
  8. Overlapping Phenotype of Adult-OnsetCardiology research · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Yishay WasserstrumLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.ORCID 0000-0001-8063-2806
José M Larrañaga-MoreiraUnidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
Cristina Martinez-VeiraUnidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
Edward ItelmanLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Dor LotanLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Avi SabbagLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Rafael KupersteinLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Yael PeledLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Dov FreimarkLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Roberto Barriales-VillaUnidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
Michael AradLeviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Tel Aviv University · ILUniversidade da Coruña · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function that is associated with worse outcomes. METHODS AND

resultsOur registry included 1328 HCM patients from two centres in Spain and Israel. Patients with normal baseline ventricular function were matched, and a competing-risk analysis was performed to find factors associated with HCMr development. Patient records were reviewed to recognize clinically significant events that occurred closely before the development of HCMr. Genetic data were collected in patients with HCMr. A composite of all-cause mortality or ventricular assist device (VAD)/heart transplantation was assessed according to ventricular function. Median age was 56, and 34% were female patients. HCMr at evaluation was seen in 37 (2.8%) patients, and 46 (3.5%) developed HCMr during median follow up of 9 years. HCMr was associated with younger age of diagnosis, poor functional class, and ventricular arrhythmia. Atrial fibrillation, pacemaker implantation, and baseline left ventricular ejection fraction (LVEF) of ≤55% were significant predictors of future HCMr development, while LV obstruction predicted a lower risk. Genetic testing performed in 53 HCMr patients, identifying one or more pathogenic variant in 38 (72%): most commonly in myosin binding protein C (n = 20). Six of these patients had an additional pathogenic variant in one of the sarcomere genes. Patients with baseline HCMr had a higher risk (hazard ratio 6.4, 4.1-10.1) for the composite outcome and for the individual components. Patients who developed HCMr in the course of the study had similar mortality but a higher rate of VAD/heart transplantation compared with HCM with normal LVEF.

conclusionsHypertrophic cardiomyopathy with reduced ejection fraction is associated with heart failure and poor outcome. Arrhythmia, cardiac surgery, and device implantation were commonly documented prior to HCMr development, suggesting they may be either a trigger or the result of adverse remodelling. Future studies should focus on prediction and prevention of HCMr.

Indexed as

Cardiomyopathy, HypertrophicHeart FailureFemaleHumansMalePhenotypePrognosisRisk FactorsStroke VolumeVentricular Function, LeftGeneticsHeart failureHypertrophic cardiomyopathySystolic dysfunction

Identifiers

PMID35488723
PMCPMC9288812
OpenAlexW4225160123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.